var data={"title":"Short-lasting unilateral neuralgiform headache attacks: Treatment","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Short-lasting unilateral neuralgiform headache attacks: Treatment</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/contributors\" class=\"contributor contributor_credentials\">Manjit S Matharu, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/contributors\" class=\"contributor contributor_credentials\">Anna S Cohen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/contributors\" class=\"contributor contributor_credentials\">Jerry W Swanson, MD, MHPE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/contributors\" class=\"contributor contributor_credentials\">John F Dashe, MD, PhD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 23, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The trigeminal autonomic cephalalgias (TACs) are a group of primary headache disorders characterized by unilateral trigeminal distribution pain that occurs in association with ipsilateral cranial autonomic features [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/1,2\" class=\"abstract_t\">1,2</a>]. The TACs include cluster headache, paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks, and hemicrania continua [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/3\" class=\"abstract_t\">3</a>]. There are two subtypes of short-lasting unilateral neuralgiform headache attacks [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/3\" class=\"abstract_t\">3</a>]: &#160;</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA)</p><p/><p>Although SUNCT and SUNA were once considered to be refractory to therapy, beneficial responses with several categories of medications have been reported in small numbers of patients. However, the evidence consists mainly of case reports and small case series.</p><p>This topic will review the treatment and prognosis of SUNCT and SUNA. The clinical features and diagnosis of these headaches are reviewed elsewhere. (See <a href=\"topic.htm?path=short-lasting-unilateral-neuralgiform-headache-attacks-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Short-lasting unilateral neuralgiform headache attacks: Clinical features and diagnosis&quot;</a>.)</p><p>Other trigeminal autonomic cephalalgias are also discussed separately. (See <a href=\"topic.htm?path=cluster-headache-epidemiology-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Cluster headache: Epidemiology, clinical features, and diagnosis&quot;</a> and <a href=\"topic.htm?path=paroxysmal-hemicrania-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Paroxysmal hemicrania: Clinical features and diagnosis&quot;</a> and <a href=\"topic.htm?path=hemicrania-continua\" class=\"medical medical_review\">&quot;Hemicrania continua&quot;</a> and <a href=\"topic.htm?path=pathophysiology-of-the-trigeminal-autonomic-cephalalgias\" class=\"medical medical_review\">&quot;Pathophysiology of the trigeminal autonomic cephalalgias&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">ACUTE MEDICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Limited data suggest that SUNCT and SUNA are responsive to inpatient treatment with parenteral <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> given for one to seven days; the supporting evidence comes from small case series. (See <a href=\"#H3\" class=\"local\">'Lidocaine'</a> below.)</p><p>In contrast, acute treatments used for other trigeminal autonomic cephalalgias, including oxygen [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/4,5\" class=\"abstract_t\">4,5</a>] and oral and intramuscular <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/5-12\" class=\"abstract_t\">5-12</a>], have not been consistently effective for SUNCT or SUNA. In addition, there is no clear benefit with the use of simple analgesics, combination analgesics, or opioids [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/4,5,13,14\" class=\"abstract_t\">4,5,13,14</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Lidocaine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Among 15 patients with short-lasting unilateral neuralgiform headache attacks (11 with SUNCT and 4 with SUNA) treated with intravenous <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> for up to seven days, partial relief to total abolition of symptoms was observed in 14 patients with a recorded response; 1 patient with SUNCT was lost to follow-up [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/15\" class=\"abstract_t\">15</a>]. Pain-free periods were variable; the shortest lasted only as long as the duration of the infusion. The longest pain-free periods were 3 weeks in a patient with chronic SUNCT, 12 weeks in a patient with chronic SUNA, and 6 months in a patient with episodic SUNCT [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/15\" class=\"abstract_t\">15</a>].</p><p>In another report of 14 patients with SUNCT or SUNA who had 17 attacks treated with <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> (14 by subcutaneous infusion and 3 by intravenous infusion), there was complete resolution of pain in 13 attacks (76 percent) [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/16\" class=\"abstract_t\">16</a>].</p><p>Intravenous <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> may be particularly useful for occasional patients with SUNCT who experience acute, severe exacerbations characterized by frequent, easily triggered, high-intensity pain [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/17,18\" class=\"abstract_t\">17,18</a>]. Such patients may not be able to eat or drink because these actions trigger attacks, and the need for acute intervention is urgent.</p><p>In addition to rapid amelioration of pain, some patients with a successful response to <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> infusion are pain-free for weeks after the infusion. This may allow a period of time for either a drug-free interval or for titration and optimization of preventive medications. (See <a href=\"#H5\" class=\"local\">'Preventive medications'</a> below.)</p><p>Therefore, we suggest intravenous <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> infusion treatment for patients with acute, severe, debilitating attacks of SUNCT or SUNA.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h3\">Administration and side effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intravenous <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> (1.5 to 3.5 <span class=\"nowrap\">mg/kg</span> per hour) is given slowly, with a loading dose of 1 <span class=\"nowrap\">mg/kg</span> over 15 minutes. The total duration of the infusion should not exceed seven days. A response is considered positive if the attacks are mostly or entirely suppressed for the duration of the infusion or longer.</p><p><a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">Lidocaine</a> infusion is associated with the potential for serious adverse events, especially when high doses are utilized [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/19-21\" class=\"abstract_t\">19-21</a>]. These events include cardiac arrhythmias, cognitive impairment, dizziness, nausea, and diarrhea. In addition, we have noticed a particular problem with frequent neuropsychiatric symptoms such as acute depression or paranoia [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/22\" class=\"abstract_t\">22</a>]. While these adverse events always resolve, they are very disturbing for patient and clinician alike.</p><p>Continuous ECG monitoring is required during intravenous administration of <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a>, and it is imperative to observe the patient carefully for adverse effects. Intravenous lidocaine should <strong>not</strong> be used in patients with any degree of cardiac conduction system abnormality or heart block who do not have an artificial pacemaker.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">PREVENTIVE MEDICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Short-lasting unilateral neuralgiform headache attacks (ie, SUNCT and SUNA) were once considered to be refractory to treatment. However, data from small open-label studies suggest that <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a>, <a href=\"topic.htm?path=topiramate-drug-information\" class=\"drug drug_general\">topiramate</a>, and <a href=\"topic.htm?path=gabapentin-drug-information\" class=\"drug drug_general\">gabapentin</a> are moderately effective as preventive therapy for SUNCT and SUNA.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Lamotrigine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">Lamotrigine</a> may be the most effective preventive medication for short-lasting unilateral neuralgiform headache attacks.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the largest study, a case series of 29 patients, treatment with <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a> (up to 400 mg daily) was associated with moderate to good response in 18 patients (62 percent), including 17 of 25 patients with SUNCT and 1 of 4 patients with SUNA [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/15\" class=\"abstract_t\">15</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another series, a good response to <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a>, defined as a &gt;50 percent reduction in headache frequency <span class=\"nowrap\">and/or</span> severity, was seen in 11 of 19 patients overall [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/16\" class=\"abstract_t\">16</a>]. The response varied according to the disease course. In the group with episodic <span class=\"nowrap\">SUNCT/SUNA,</span> a good response to lamotrigine was seen in 9 of 10 patients. However, in the chronic group, defined by attacks occurring for more than one year without remission or with remission lasting less than one month, a good response was obtained in only one of nine patients.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In several other case series and case reports of patients with SUNCT, <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a> (up to 300 mg daily) was reported as effective in 10 patients [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/13,23-26\" class=\"abstract_t\">13,23-26</a>], and ineffective in 4 patients [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/5,27,28\" class=\"abstract_t\">5,27,28</a>]. Lamotrigine (400 mg daily) was also ineffective in a patient with secondary SUNCT related to trigeminal nerve compression [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/7\" class=\"abstract_t\">7</a>].</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Dose and side effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The usual starting dose of <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a> is 25 mg daily for the first two weeks of treatment, then 50 mg daily for weeks three and four. The dose is thereafter titrated to effect and tolerance. After week four, the daily dose can be increased by 50 mg every one to two weeks. The usual maintenance dose is 200 mg daily given in two divided doses, but total daily doses up to 400 mg given in two divided doses have been used.</p><p>Systemic side effects of <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a> include rash and nausea. A benign rash may develop in up to 10 percent of patients during the initial one to two months of therapy and necessitates discontinuation of the drug. The risk of developing a life-threatening rash such as Stevens-Johnson syndrome, toxic epidermal necrolysis, or angioedema is approximately 1 in 1000 adults; this risk is increased in children.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Topiramate</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=topiramate-drug-information\" class=\"drug drug_general\">Topiramate</a> may be useful as a preventive medication for short-lasting unilateral neuralgiform headache attacks.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the largest case series of 22 patients with SUNCT (n = 21) or SUNA (n = 1), treatment with <a href=\"topic.htm?path=topiramate-drug-information\" class=\"drug drug_general\">topiramate</a> (up to 400 mg daily) was associated with a good response in 11 (50 percent) [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/15\" class=\"abstract_t\">15</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a blinded crossover trial, <a href=\"topic.htm?path=topiramate-drug-information\" class=\"drug drug_general\">topiramate</a> (100 mg daily in two divided doses) was beneficial for two of five patients with SUNCT, compared with one of five who improved with placebo [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/29\" class=\"abstract_t\">29</a>].</p><p/><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">Dose and side effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The usual starting dose of <a href=\"topic.htm?path=topiramate-drug-information\" class=\"drug drug_general\">topiramate</a> is 15 to 25 mg daily; the dose can be increased to 400 mg daily in two divided doses over eight weeks. However, the optimal dose for SUNCT and SUNA is unknown.</p><p>Weight loss is a common side effect of <a href=\"topic.htm?path=topiramate-drug-information\" class=\"drug drug_general\">topiramate</a>. Impaired cognition is a reversible side effect observed in a minority of patients taking topiramate, but it is a common reason for discontinuing therapy. Metabolic acidosis and tachypnea may result from renal bicarbonate loss due to the inhibitory effect of topiramate on carbonic anhydrase; patients taking topiramate for prolonged periods may develop kidney stones due to carbonic anhydrase inhibition. Additional side effects include paresthesias, headache, fatigue, dizziness, depression, and mood problems. Acute myopia and secondary angle closure glaucoma are rare side effects.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Gabapentin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=gabapentin-drug-information\" class=\"drug drug_general\">Gabapentin</a> may useful as preventive therapy in SUNCT and SUNA.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a series of 27 patients with SUNCT or SUNA, treatment with <a href=\"topic.htm?path=gabapentin-drug-information\" class=\"drug drug_general\">gabapentin</a> (up to 3600 mg daily) was associated with a good response in 13 (48 percent) [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/15\" class=\"abstract_t\">15</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An open-label study of <a href=\"topic.htm?path=gabapentin-drug-information\" class=\"drug drug_general\">gabapentin</a> (up to 900 mg daily) reported complete remission of SUNCT attacks in five of eight patients [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/30\" class=\"abstract_t\">30</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In other case series and case reports, <a href=\"topic.htm?path=gabapentin-drug-information\" class=\"drug drug_general\">gabapentin</a> (800 to 2700 mg daily) was associated with complete suppression of SUNCT attacks in three patients [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/9,31,32\" class=\"abstract_t\">9,31,32</a>], but was ineffective in another eight patients [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/4,5,13\" class=\"abstract_t\">4,5,13</a>], and ineffective for one patient with secondary SUNCT associated with compression of the trigeminal nerve [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/7\" class=\"abstract_t\">7</a>]. In a patient with SUNA, gabapentin was minimally effective at an unknown dose [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/11\" class=\"abstract_t\">11</a>].</p><p/><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Dose and side effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although regimens vary, we start with an initial dose of <a href=\"topic.htm?path=gabapentin-drug-information\" class=\"drug drug_general\">gabapentin</a> 300 mg daily, increasing gradually to 300 mg twice a day and then to 300 mg three times a day. Thereafter, the dose is increased slowly as needed to 1800 mg a day in three divided doses, although some patients require total doses up to 3600 mg daily. In neuropathic pain conditions, typical maintenance gabapentin doses range from 900 to 2400 <span class=\"nowrap\">mg/day,</span> and the drug is usually well tolerated at doses up to 3600 mg daily when titrated up cautiously.</p><p>The major side effect of <a href=\"topic.htm?path=gabapentin-drug-information\" class=\"drug drug_general\">gabapentin</a> is sedation. Others include diarrhea, mood swings, ataxia, fatigue, nausea, and dizziness.</p><p class=\"headingAnchor\" id=\"H4615814\"><span class=\"h2\">Others</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A variety of other medications, alone or in combination, have been employed to treat SUNCT and SUNA, including <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/4,5,7,8,15,33,34\" class=\"abstract_t\">4,5,7,8,15,33,34</a>], <a href=\"topic.htm?path=oxcarbazepine-drug-information\" class=\"drug drug_general\">oxcarbazepine</a> [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/35,36\" class=\"abstract_t\">35,36</a>], <a href=\"topic.htm?path=clomiphene-drug-information\" class=\"drug drug_general\">clomiphene</a> [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/37,38\" class=\"abstract_t\">37,38</a>], <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">valproate</a> [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/5,11,39,40\" class=\"abstract_t\">5,11,39,40</a>], <a href=\"topic.htm?path=verapamil-drug-information\" class=\"drug drug_general\">verapamil</a> [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/12,41,42\" class=\"abstract_t\">12,41,42</a>], <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, <a href=\"topic.htm?path=zonisamide-drug-information\" class=\"drug drug_general\">zonisamide</a> [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/43\" class=\"abstract_t\">43</a>], <a href=\"topic.htm?path=onabotulinumtoxina-botox-drug-information\" class=\"drug drug_general\">onabotulinumtoxinA</a> (botulinum toxin A) injections [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/44\" class=\"abstract_t\">44</a>], and glucocorticoids [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/4,8,10,18,45,46\" class=\"abstract_t\">4,8,10,18,45,46</a>]. However, none has been consistently effective.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Treatment choice</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Given the available but limited data, we suggest <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a> as initial preventive medical therapy in patients with frequent or debilitating attacks of SUNCT or SUNA. <a href=\"topic.htm?path=topiramate-drug-information\" class=\"drug drug_general\">Topiramate</a> and <a href=\"topic.htm?path=gabapentin-drug-information\" class=\"drug drug_general\">gabapentin</a> are reasonable alternatives. (See <a href=\"#H6\" class=\"local\">'Lamotrigine'</a> above and <a href=\"#H8\" class=\"local\">'Topiramate'</a> above and <a href=\"#H10\" class=\"local\">'Gabapentin'</a> above.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">SURGERY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several surgical approaches have been attempted for the treatment of SUNCT syndrome. These take the form either of local blockades, invasive procedures involving the trigeminal nerve, or neuromodulatory procedures using superficial nerve and deep brain stimulation.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Greater occipital nerve blockade and stimulation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nociceptive pathways in the head involve an important interaction between trigeminal and cervical afferents in the trigeminocervical complex [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/47,48\" class=\"abstract_t\">47,48</a>]. This mechanism might be involved in the referral of pain from trigeminal to cervical structures. Thus, either greater occipital nerve blockade or stimulation may play a role in modulating these trigeminocervical connections.</p><p>Though the mechanism of action of the two treatment modalities is poorly understood, they probably work by completely different mechanisms. Greater occipital nerve blockade reduces afferent traffic along the trigeminal-occipital input, while occipital nerve stimulation increases traffic along this pathway and probably acts by bringing about neuroplastic changes in the pain network.</p><p>While greater occipital nerve procedures may be beneficial for short-lasting unilateral neuralgiform headache attacks, the evidence is limited:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the largest reported series, a single greater occipital nerve injection with 2 percent <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> and 80 mg <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> was associated with a good response in five of nine patients with SUNCT or SUNA [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/15\" class=\"abstract_t\">15</a>]. In patients responsive to treatment, pain-free times ranged from one week to six months.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In other reports, <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> blockade of the greater occipital nerve was ineffective in two patients with SUNCT [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/40\" class=\"abstract_t\">40</a>] but was associated with a good response in another patient with SUNCT [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/49\" class=\"abstract_t\">49</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a retrospective study, patients with medically intractable SUNCT (n = 6) and SUNA (n = 1) were treated with bilateral occipital nerve stimulation [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/50\" class=\"abstract_t\">50</a>]. At a median follow-up of 24 months, substantial improvement was reported for four patients and moderate improvement for one patient. The procedure was well-tolerated, though one patient developed hemicrania continua one month after implantation and was successfully treated with <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a>.</p><p/><p>Given the small numbers of patients studied, treatment of short-lasting unilateral neuralgiform headache with greater occipital nerve procedures (either blockade or stimulation) should be considered investigational.</p><p class=\"headingAnchor\" id=\"H21940101\"><span class=\"h2\">Other local blockades</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Local blockades of other pericranial nerves (supra-orbital, infra-orbital, lacrimal), the retrobulbar region, pericranial ganglia (stellate, pterygopalatine, superior cervical) and orbicularis oculi muscles have generally been ineffective [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/40,51,52\" class=\"abstract_t\">40,51,52</a>].</p><p class=\"headingAnchor\" id=\"H24030013\"><span class=\"h2\">Trigeminal microvascular decompression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Small studies, mainly case reports, have suggested that trigeminal microvascular decompression is beneficial for patients with refractory short-lasting unilateral neuralgiform headache attacks who have an abnormal vascular loop in contact with the symptomatic trigeminal nerve at the root entry zone [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/53\" class=\"abstract_t\">53</a>]. One of the largest series reported nine patients with intractable <span class=\"nowrap\">SUNCT/SUNA</span> [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/54\" class=\"abstract_t\">54</a>]. At 9 to 32 months (mean 22) of follow-up after microvascular decompression, there was complete relief of pain for six of the nine patients, and complications were minimal. While more long-term studies are required, these data suggest that trigeminal microvascular decompression is a viable treatment option in patients with aberrant loops impinging on the ipsilateral trigeminal nerve.</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Destructive trigeminal nerve procedures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In our experience, invasive, destructive trigeminal nerve procedures are of no value or are harmful in patients with <span class=\"nowrap\">SUNCT/SUNA</span>. The available evidence is limited to a few patients who were treated with glycerol rhizotomy, gamma knife radiosurgery, or radiofrequency thermocoagulation of the trigeminal nerve [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/5,10,27,54\" class=\"abstract_t\">5,10,27,54</a>]. Some authorities recommend that trigeminal surgery be considered only as a last resort, and then with extreme caution, given its uncertain outcomes and the potential for debilitating side effects. However, our view is that destructive procedures have no place in the current management of SUNCT and SUNA.</p><p class=\"headingAnchor\" id=\"H21939939\"><span class=\"h2\">Deep brain stimulation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Functional imaging studies found that activation of the posterior hypothalamus was linked to attacks of SUNCT [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/28,55\" class=\"abstract_t\">28,55</a>] suggesting that deep brain stimulation (DBS) might be a therapeutic option [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/56,57\" class=\"abstract_t\">56,57</a>]. Other reports suggested that the midbrain tegmentum might be the preferred target of DBS [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/58\" class=\"abstract_t\">58</a>]. (See <a href=\"topic.htm?path=pathophysiology-of-the-trigeminal-autonomic-cephalalgias\" class=\"medical medical_review\">&quot;Pathophysiology of the trigeminal autonomic cephalalgias&quot;</a>.)</p><p>In one uncontrolled observational study, 11 patients with refractory short-lasting unilateral neuralgiform headache attacks were treated with ipsilateral DBS targeting the ventral tegmental area of the midbrain [<a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/59\" class=\"abstract_t\">59</a>]. Treatment was associated with a median reduction in daily attack frequency of 78 percent. The response rate, defined as the proportion of patients with a &ge;50 percent improvement in daily attack frequency, was 82 percent.</p><p>Although these results are promising, further study is needed to evaluate the utility of DBS for patients with SUNCT and SUNA.</p><p class=\"headingAnchor\" id=\"H2414343854\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-migraine-and-other-primary-headache-disorders\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Migraine and other primary headache disorders&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are two subtypes of short-lasting unilateral neuralgiform headache attacks (see <a href=\"#H1\" class=\"local\">'Introduction'</a> above): &#160;</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>SUNCT and SUNA may respond to acute treatment with intravenous <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a>. Acute treatments used for other trigeminal autonomic cephalalgias, including oxygen and <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a>, have not been consistently effective for SUNCT or SUNA. (See <a href=\"#H2\" class=\"local\">'Acute medications'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with acute, severe, debilitating attacks of SUNCT or SUNA, we suggest acute treatment with intravenous <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> infusion (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Continuous electrocardiogram (ECG) monitoring is required during intravenous lidocaine administration, along with close observation for adverse effects. (See <a href=\"#H3\" class=\"local\">'Lidocaine'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Data from small open-label studies suggest that <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a>, <a href=\"topic.htm?path=topiramate-drug-information\" class=\"drug drug_general\">topiramate</a>, and <a href=\"topic.htm?path=gabapentin-drug-information\" class=\"drug drug_general\">gabapentin</a> are moderately effective as preventive therapy for SUNCT and SUNA. A variety of other medications, alone or in combination, have also been employed to treat SUNCT and SUNA, including <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>, <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">valproate</a>, <a href=\"topic.htm?path=verapamil-drug-information\" class=\"drug drug_general\">verapamil</a>, <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, and glucocorticoids, though none has been consistently effective. (See <a href=\"#H5\" class=\"local\">'Preventive medications'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with frequent or debilitating attacks of SUNCT or SUNA, we suggest initial preventive medical therapy with <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a> (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). For patients who do not respond to or tolerate lamotrigine, reasonable alternative preventive treatments are <a href=\"topic.htm?path=topiramate-drug-information\" class=\"drug drug_general\">topiramate</a> and <a href=\"topic.htm?path=gabapentin-drug-information\" class=\"drug drug_general\">gabapentin</a>. (See <a href=\"#H6\" class=\"local\">'Lamotrigine'</a> above and <a href=\"#H8\" class=\"local\">'Topiramate'</a> above and <a href=\"#H10\" class=\"local\">'Gabapentin'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There is only limited evidence regarding greater occipital nerve procedures for the treatment of short-lasting unilateral neuralgiform headache. (See <a href=\"#H14\" class=\"local\">'Greater occipital nerve blockade and stimulation'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/1\" class=\"nounderline abstract_t\">Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain 1997; 120 ( Pt 1):193.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/2\" class=\"nounderline abstract_t\">Goadsby PJ. Trigeminal autonomic cephalalgias. Pathophysiology and classification. Rev Neurol (Paris) 2005; 161:692.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/3\" class=\"nounderline abstract_t\">Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33:629.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/4\" class=\"nounderline abstract_t\">Matharu MS, Cohen AS, Boes CJ, Goadsby PJ. Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing syndrome: a review. Curr Pain Headache Rep 2003; 7:308.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/5\" class=\"nounderline abstract_t\">Matharu MS, Cohen AS, Goadsby PJ. SUNCT syndrome responsive to intravenous lidocaine. Cephalalgia 2004; 24:985.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/6\" class=\"nounderline abstract_t\">Prakash KM, Lo YL. SUNCT syndrome in association with persistent Horner syndrome in a Chinese patient. Headache 2004; 44:256.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/7\" class=\"nounderline abstract_t\">K&ouml;seoglu E, Karaman Y, K&uuml;c&uuml;k S, Arman F. SUNCT syndrome associated with compression of trigeminal nerve. Cephalalgia 2005; 25:473.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/8\" class=\"nounderline abstract_t\">Rossi P, Cesarino F, Faroni J, et al. SUNCT syndrome successfully treated with topiramate: case reports. Cephalalgia 2003; 23:998.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/9\" class=\"nounderline abstract_t\">Hunt CH, Dodick DW, Bosch EP. SUNCT responsive to gabapentin. Headache 2002; 42:525.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/10\" class=\"nounderline abstract_t\">Gardella L, Viruega A, Rojas H, Nagel J. A case of a patient with SUNCT syndrome treated with Jannetta procedure. Cephalalgia 2001; 21:996.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/11\" class=\"nounderline abstract_t\">Volcy M, Tepper SJ, Rapoport AM, et al. Short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA)--a case report. Cephalalgia 2005; 25:470.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/12\" class=\"nounderline abstract_t\">Narbone MC, Gangemi S, Abbate M. A case of SUNCT syndrome responsive to verapamil. Cephalalgia 2005; 25:476.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/13\" class=\"nounderline abstract_t\">Malik K, Rizvi S, Vaillancourt PD. The SUNCT syndrome: successfully treated with lamotrigine. Pain Med 2002; 3:167.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/14\" class=\"nounderline abstract_t\">Putzki N, Nirkko A, Diener HC. Trigeminal autonomic cephalalgias: a case of post-traumatic SUNCT syndrome? Cephalalgia 2005; 25:395.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/15\" class=\"nounderline abstract_t\">Cohen AS. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing. Cephalalgia 2007; 27:824.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/16\" class=\"nounderline abstract_t\">Williams MH, Broadley SA. SUNCT and SUNA: clinical features and medical treatment. J Clin Neurosci 2008; 15:526.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/17\" class=\"nounderline abstract_t\">Pareja JA, Caballero V, Sjaastad O. SUNCT syndrome. Statuslike pattern. Headache 1996; 36:622.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/18\" class=\"nounderline abstract_t\">Montes E, Alberca R, Lozano P, et al. Statuslike SUNCT in two young women. Headache 2001; 41:826.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/19\" class=\"nounderline abstract_t\">Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991; 41:1024.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/20\" class=\"nounderline abstract_t\">Ferrante FM, Paggioli J, Cherukuri S, Arthur GR. The analgesic response to intravenous lidocaine in the treatment of neuropathic pain. Anesth Analg 1996; 82:91.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/21\" class=\"nounderline abstract_t\">Wallace MS, Dyck JB, Rossi SS, Yaksh TL. Computer-controlled lidocaine infusion for the evaluation of neuropathic pain after peripheral nerve injury. Pain 1996; 66:69.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/22\" class=\"nounderline abstract_t\">Gil-Gouveia R, Goadsby PJ. Neuropsychiatric side-effects of lidocaine: examples from the treatment of headache and a review. Cephalalgia 2009; 29:496.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/23\" class=\"nounderline abstract_t\">D'Andrea G, Granella F, Cadaldini M. Possible usefulness of lamotrigine in the treatment of SUNCT syndrome. Neurology 1999; 53:1609.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/24\" class=\"nounderline abstract_t\">Leone M, Rigamonti A, Usai S, et al. Two new SUNCT cases responsive to lamotrigine. Cephalalgia 2000; 20:845.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/25\" class=\"nounderline abstract_t\">D'Andrea G, Granella F, Ghiotto N, Nappi G. Lamotrigine in the treatment of SUNCT syndrome. Neurology 2001; 57:1723.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/26\" class=\"nounderline abstract_t\">Gutierrez-Garcia JM. SUNCT syndrome responsive to lamotrigine. Headache 2002; 42:823.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/27\" class=\"nounderline abstract_t\">Black DF, Dodick DW. Two cases of medically and surgically intractable SUNCT: a reason for caution and an argument for a central mechanism. Cephalalgia 2002; 22:201.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/28\" class=\"nounderline abstract_t\">Sprenger T, Valet M, Platzer S, et al. SUNCT: bilateral hypothalamic activation during headache attacks and resolving of symptoms after trigeminal decompression. Pain 2005; 113:422.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/29\" class=\"nounderline abstract_t\">Cohen AS, Matharu MS, Goadsby PJ. Double-blind placebo-controlled trial of topiramate in SUNCT. Cephalalgia 2007; 27:758.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/30\" class=\"nounderline abstract_t\">Etemadifar M, Maghzi AH, Ghasemi M, et al. Efficacy of gabapentin in the treatment of SUNCT syndrome. Cephalalgia 2008; 28:1339.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/31\" class=\"nounderline abstract_t\">Graff-Radford SB. SUNCT syndrome responsive to gabapentin (Neurontin). Cephalalgia 2000; 20:515.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/32\" class=\"nounderline abstract_t\">Porta-Etessam J, Martinez-Salio A, Berbel A, Benito-Leon J. Gabapentin (neuronetin) in the treatment of SUNCT syndrome. Cephalalgia 2002; 22:249; author reply 249.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/33\" class=\"nounderline abstract_t\">Cohen AS, Matharu MS, Goadsby PJ. SUNCT syndrome in the elderly. Cephalalgia 2004; 24:508.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/34\" class=\"nounderline abstract_t\">Gantenbein AR, Goadsby PJ. Familial SUNCT. Cephalalgia 2005; 25:457.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/35\" class=\"nounderline abstract_t\">Marziniak M, Breyer R, Evers S. SUNCT syndrome successfully treated with the combination of oxcarbazepine and gabapentin. Pain Med 2009; 10:1497.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/36\" class=\"nounderline abstract_t\">Dora B. SUNCT syndrome with dramatic response to oxcarbazepine. Cephalalgia 2006; 26:1171.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/37\" class=\"nounderline abstract_t\">Rozen TD, Saper JR, Sheftell FD, Dodick DW. Clomiphene citrate as a new treatment for SUNCT: hormonal manipulation for hypothalamic-influenced trigeminal autonomic cephalalgias. Headache 2005; 45:754.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/38\" class=\"nounderline abstract_t\">Rozen TD. Complete alleviation of treatment refractory primary SUNCT syndrome with clomiphene citrate (a medicinal deep brain hypothalamic modulator). Cephalalgia 2014; 34:1021.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/39\" class=\"nounderline abstract_t\">Sesso RM. SUNCT syndrome or trigeminal neuralgia with lacrimation and conjunctival injection? Cephalalgia 2001; 21:151.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/40\" class=\"nounderline abstract_t\">Pareja JA, Kruszewski P, Sjaastad O. SUNCT syndrome: trials of drugs and anesthetic blockades. Headache 1995; 35:138.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/41\" class=\"nounderline abstract_t\">Jim&eacute;nez-Huete A, Franch O, Pareja JA. SUNCT syndrome: priming of symptomatic periods and worsening of symptoms by treatment with calcium channel blockers. Cephalalgia 2002; 22:812.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/42\" class=\"nounderline abstract_t\">May A, Bahra A, B&uuml;chel C, et al. Functional magnetic resonance imaging in spontaneous attacks of SUNCT: short-lasting neuralgiform headache with conjunctival injection and tearing. Ann Neurol 1999; 46:791.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/43\" class=\"nounderline abstract_t\">Ikawa M, Imai N, Manaka S. A case of SUNCT syndrome responsive to zonisamide. Cephalalgia 2011; 31:501.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/44\" class=\"nounderline abstract_t\">Zabalza RJ. Sustained response to botulinum toxin in SUNCT syndrome. Cephalalgia 2012; 32:869.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/45\" class=\"nounderline abstract_t\">Calvo JF, Bruera OC, de Lourdes Figuerola M, et al. SUNCT syndrome: clinical and 12-year follow-up case report. Cephalalgia 2004; 24:900.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/46\" class=\"nounderline abstract_t\">Trauninger A, Alkonyi B, Kov&aacute;cs N, et al. Methylprednisolone therapy for short-term prevention of SUNCT syndrome. Cephalalgia 2010; 30:735.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/47\" class=\"nounderline abstract_t\">Goadsby PJ. Migraine pathophysiology. Headache 2005; 45 Suppl 1:S14.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/48\" class=\"nounderline abstract_t\">Goadsby PJ, Bartsch T, Dodick DW. Occipital nerve stimulation for headache: mechanisms and efficacy. Headache 2008; 48:313.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/49\" class=\"nounderline abstract_t\">Porta-Etessam J, Cuadrado ML, Gal&aacute;n L, et al. Temporal response to bupivacaine bilateral great occipital block in a patient with SUNCT syndrome. J Headache Pain 2010; 11:179.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/50\" class=\"nounderline abstract_t\">Matharu M, Watkins L, Shanahan P. POH04 Treatment of medically intractable SUNCT and SUNA with occipital nerve stimulation. J Neurol Neurosurg Psychiatry 2010; 81:e51.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/51\" class=\"nounderline abstract_t\">Sabatowski R, Huber M, Meuser T, Radbruch L. SUNCT syndrome: a treatment option with local opioid blockade of the superior cervical ganglion? A case report. Cephalalgia 2001; 21:154.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/52\" class=\"nounderline abstract_t\">Hannerz J, Linderoth B. Neurosurgical treatment of short-lasting, unilateral, neuralgiform hemicrania with conjunctival injection and tearing. Br J Neurosurg 2002; 16:55.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/53\" class=\"nounderline abstract_t\">Sebastian S, Schweitzer D, Tan L, Broadley SA. Role of trigeminal microvascular decompression in the treatment of SUNCT and SUNA. Curr Pain Headache Rep 2013; 17:332.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/54\" class=\"nounderline abstract_t\">Williams M, Bazina R, Tan L, et al. Microvascular decompression of the trigeminal nerve in the treatment of SUNCT and SUNA. J Neurol Neurosurg Psychiatry 2010; 81:992.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/55\" class=\"nounderline abstract_t\">May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 1999; 19:115.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/56\" class=\"nounderline abstract_t\">Leone M, Franzini A, D'Andrea G, et al. Deep brain stimulation to relieve drug-resistant SUNCT. Ann Neurol 2005; 57:924.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/57\" class=\"nounderline abstract_t\">Lyons MK, Dodick DW, Evidente VG. Responsiveness of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing to hypothalamic deep brain stimulation. J Neurosurg 2009; 110:279.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/58\" class=\"nounderline abstract_t\">Matharu MS, Zrinzo L. Deep brain stimulation in cluster headache: hypothalamus or midbrain tegmentum? Curr Pain Headache Rep 2010; 14:151.</a></li><li><a href=\"https://www.uptodate.com/contents/short-lasting-unilateral-neuralgiform-headache-attacks-treatment/abstract/59\" class=\"nounderline abstract_t\">Miller S, Akram H, Lagrata S, et al. Ventral tegmental area deep brain stimulation in refractory short-lasting unilateral neuralgiform headache attacks. Brain 2016; 139:2631.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3338 Version 13.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H18\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">ACUTE MEDICATIONS</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Lidocaine</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">- Administration and side effects</a></li></ul></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">PREVENTIVE MEDICATIONS</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">Lamotrigine</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">- Dose and side effects</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">Topiramate</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">- Dose and side effects</a></li></ul></li><li><a href=\"#H10\" id=\"outline-link-H10\">Gabapentin</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">- Dose and side effects</a></li></ul></li><li><a href=\"#H4615814\" id=\"outline-link-H4615814\">Others</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Treatment choice</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">SURGERY</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">Greater occipital nerve blockade and stimulation</a></li><li><a href=\"#H21940101\" id=\"outline-link-H21940101\">Other local blockades</a></li><li><a href=\"#H24030013\" id=\"outline-link-H24030013\">Trigeminal microvascular decompression</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Destructive trigeminal nerve procedures</a></li><li><a href=\"#H21939939\" id=\"outline-link-H21939939\">Deep brain stimulation</a></li></ul></li><li><a href=\"#H2414343854\" id=\"outline-link-H2414343854\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=cluster-headache-epidemiology-clinical-features-and-diagnosis\" class=\"medical medical_review\">Cluster headache: Epidemiology, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hemicrania-continua\" class=\"medical medical_review\">Hemicrania continua</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=paroxysmal-hemicrania-clinical-features-and-diagnosis\" class=\"medical medical_review\">Paroxysmal hemicrania: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-of-the-trigeminal-autonomic-cephalalgias\" class=\"medical medical_review\">Pathophysiology of the trigeminal autonomic cephalalgias</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=short-lasting-unilateral-neuralgiform-headache-attacks-clinical-features-and-diagnosis\" class=\"medical medical_review\">Short-lasting unilateral neuralgiform headache attacks: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-migraine-and-other-primary-headache-disorders\" class=\"medical medical_society_guidelines\">Society guideline links: Migraine and other primary headache disorders</a></li></ul></div></div>","javascript":null}